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Background Selective cyclooxygenase-2 inhibitors and conventional non-selective non-steroidal anti-inflammatory drugs
(nsNSAIDs) have been associated with adverse cardiovascular (CV) effects. We compared the CV safety of switch-
ing to celecoxib vs. continuing nsNSAID therapy in a European setting.
...................................................................................................................................................................................................
Method Patients aged 60 years and over with osteoarthritis or rheumatoid arthritis, free from established CV disease and
taking chronic prescribed nsNSAIDs, were randomized to switch to celecoxib or to continue their previous
nsNSAID. The primary endpoint was hospitalization for non-fatal myocardial infarction or other biomarker positive
acute coronary syndrome, non-fatal stroke or CV death analysed using a Cox model with a pre-specified non-infe-
riority limit of 1.4 for the hazard ratio (HR).
...................................................................................................................................................................................................
Results In total, 7297 participants were randomized. During a median 3-year follow-up, fewer subjects than expected
developed an on-treatment (OT) primary CV event and the rate was similar for celecoxib, 0.95 per 100 patient-
years, and nsNSAIDs, 0.86 per 100 patient-years (HR ¼ 1.12, 95% confidence interval, 0.81–1.55; P ¼ 0.50).
Comparable intention-to-treat (ITT) rates were 1.14 per 100 patient-years with celecoxib and 1.10 per 100
patient-years with nsNSAIDs (HR¼ 1.04; 95% confidence interval, 0.81–1.33; P¼ 0.75). Pre-specified non-inferiority
was achieved in the ITT analysis. The upper bound of the 95% confidence limit for the absolute increase in OT risk
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associated with celecoxib treatment was two primary events per 1000 patient-years exposure. There were only 15
adjudicated secondary upper gastrointestinal complication endpoints (0.078/100 patient-years on celecoxib vs.
0.053 on nsNSAIDs OT, 0.078 vs. 0.053 ITT). More gastrointestinal serious adverse reactions and haematological
adverse reactions were reported on nsNSAIDs than celecoxib, but more patients withdrew from celecoxib than
nsNSAIDs (50.9% patients vs. 30.2%; P< 0.0001).
...................................................................................................................................................................................................
Interpretation In subjects 60 years and over, free from CV disease and taking prescribed chronic nsNSAIDs, CV events were
infrequent and similar on celecoxib and nsNSAIDs. There was no advantage of a strategy of switching prescribed
nsNSAIDs to prescribed celecoxib. This study excluded an increased risk of the primary endpoint of more than
two events per 1000 patient-years associated with switching to prescribed celecoxib.
...................................................................................................................................................................................................
Clinical Trial
Registration
https://clinicaltrials.gov/show/NCT00447759; Unique identifier: NCT00447759.
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Introduction
The safety of non-steroidal anti-inflammatory drugs (NSAIDs) has
been the topic of much debate. Hospitalization for NSAID-
associated upper gastrointestinal (GI) tract ulceration was previously
a common serious adverse event and selective cyclo-oxygenase 2
(COX-2) inhibitors gained popularity because they caused a lower
incidence of these complications compared with non-selective
NSAIDs (nsNSAIDs).1 However, COX-2 inhibitors were associated
with higher cardiovascular (CV) risks than nsNSAIDs.2–4 This led the
US Food and Drug Administration to strengthen warnings on all
NSAIDs5 and the European Medicines Agency (EMA) to contraindi-
cate COX-2 selective drugs in subjects with established CV
disease.6,7
We conducted the Standard care vs. Celecoxib Outcome Trial
(SCOT), which randomized patients free from established CV
disease to switch to celecoxib or to remain on their prescribed
nsNSAID, to clarify the risk–benefit balance of switching to
celecoxib.
Methods and analysis
Trial design
The SCOT trial used a Prospective, Randomized, Open label, Blinded
Endpoint evaluation (PROBE) design8 to compare the CV and GI
safety of continuing prescribed nsNSAID therapy vs. switching to
prescribed celecoxib in individuals with osteoarthritis or rheumatoid
arthritis. The study was unusual in incorporating many pragmatic fea-
tures: there were no study visits after randomization; study treat-
ments were prescribed by primary care physicians and dispensed in
community pharmacies; blood samples to assess suitability for inclu-
sion were analysed in health service laboratories; follow-up used
electronic medical records of hospitalizations and deaths; and there
were no special study-specific procedures to ensure adherence to
study medication. The aim was to mimic normal clinical practice and
normal patient behaviour. The protocol has been published.9
The trial was mandated by the EMA with a requirement that it be
conducted in at least two member states. It was conducted in the
UK, Denmark, and the Netherlands and included patients aged 60
years or over, free from significant CV disease (a history of coronary
or cerebrovascular disease or New York Heart Association class III
or IV heart failure). The trial inclusion and exclusion criteria are listed
in the Supplementary material online, Tables S1 and S2, respectively.
Potential participants were identified in primary care. Those who
responded to an invitation letter to participate, gave consent, and sat-
isfied inclusion and exclusion criteria were randomly assigned to
switch to prescribed celecoxib (the celecoxib group) or to continue
their usual prescribed nsNSAID (the nsNSAID group) using a central
randomization system. All medication was either free to patients or
fully reimbursed (see Supplementary material online, Supplementary
methods). Subjects could optionally provide a sample of serum and
blood for later analyses of lipids and uric acid levels.
Prescribed nsNSAIDs with an estimated frequency of usage of
>12% (ibuprofen and diclofenac) were assigned to unique strata and
other NSAIDs were pooled into a single stratum for the purpose of
randomization. Randomization was also stratified by osteoarthritis or
rheumatoid arthritis status. Within strata, treatment groups were
allocated randomly in equal numbers in permuted blocks of 4.
The trial treatments were prescribed at approved doses and
adjusted as clinically indicated. If pain-relief was inadequate, non-
NSAID analgesics could be added and antacid or ulcer healing ther-
apy was prescribed as required. All prescriptions in the UK were
provided free of charge and in Denmark and The Netherlands sub-
jects were reimbursed any prescription costs.
The primary endpoint was the composite of hospitalization for
non-fatal myocardial infarction or other biomarker positive acute
coronary syndrome, non-fatal stroke or CV death.
Secondary outcomes were hospitalization or death for upper GI
ulcer complications (bleeding, perforation, or obstruction);
hospitalized upper GI ulcer complications or primary outcome; hos-
pitalization for heart failure; hospitalization for heart failure or pri-
mary outcome; death from any cause; new or worsening renal failure;
hospitalization for critical limb ischemia; hospitalization for pulmo-
nary embolism.
1844 T.M. MacDonald et al.
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The principal method of follow-up in the SCOT was by record-link-
age10 (see Supplementary material online, Supplementary methods).
Treatment-related adverse events and all serious adverse events
reported by study sites were recorded and reconciled with the
record-linkage data. For potential endpoints, support documentation
was retrieved from hospital records, de-identified and reviewed by
CV or GI endpoint committees.
Statistical methods
Baseline characteristics were compared using two-sample t-tests (or
Mann–Whitney tests) and v2 (or Fisher’s exact) tests, as appropriate.
Annual incidence rate per 100 patient-years at risk is reported and
Cox proportional hazards models were used to analyse time-to-first-
event data, including the baseline NSAID and the osteoarthritis/
rheumatoid arthritis strata and the randomized treatment group as
covariates. Where the number of events was <30, the Cox model
was replaced by an exact Poisson regression model, adjusting for the
same variables with the logarithm of time as an offset. Statistical signifi-
cance was based on the Wald statistic, and two-sided 95% confidence
intervals (CIs) for the estimated hazard ratio (HR) (or rate ratio for
the Poisson model). Absolute treatment effects were estimated from
additive Poisson regression models adjusted for over-dispersion.
The main non-inferiority analysis for the primary and secondary
outcomes used on-treatment comparisons. The final study design
(see Supplementary material online, Supplementary methods) had a
non-inferiority limit HR of 1.4 for the primary CV endpoint requiring
277 first primary endpoints for 80% power. On-treatment analyses
censored subjects after the first of, discontinuation from the random-
ized treatment group (for the nsNSAID group this involved with-
drawal from any nsNSAID; see Supplementary material online,
Supplementary methods), death, withdrawal of consent, or end-of-
study date. These analyses were supported by a modified intention-
to-treat (ITT) analysis censoring on the first of death, withdrawal of
consent for follow-up, or end-of-study date.
Treatment-by-subgroup interactions were tested in Cox models
(or by exact Poisson regression analysis) incorporating subgroup-by-
treatment interactions. Subgroups where the SAS programs of tests
for interaction or for estimation of risk ratios failed are not reported.
Subgroups with inadequate events are not reported. Time-to-event
curves were estimated by the Kaplan–Meier method.
Role of the funding source
SCOT was an academic study, funded through an Investigator
Initiated Research Grant, by Pfizer. The University of Dundee was the
study sponsor and monitored and quality assured the study. The pro-
tocol was developed and owned by the Trial Steering Committee.
The sponsor and the Trial Steering Committee were wholly responsi-
ble for data collection, trial management, analysis and interpretation of
data, writing of the report and submission of the report for publication
and Pfizer played no role in any of these activities. Study data were col-
lected, managed, and analysed at the Robertson Centre for
Biostatistics, Glasgow Clinical Trials Unit, University of Glasgow.
Participants provided written informed consent. The trial was
approved by the UK Multi-Centre Research Ethics Committee (refer-
ence number: 2006-005735-24) and by relevant authorities in
Denmark and the Netherlands. Record linkage was approved by
information governance committees in the participating countries. It
was registered on ClinicalTrials.gov (reference number:
NCT00447759).
Results
We screened and gained consent from 8872 subjects between 29
January 2008 and 27 March 2013 and randomized 7297 across 9 trial
centres and 706 primary care practices (see Supplementary material
online, Figure S1). Thirty-three per cent of subjects judged to be eligi-
ble by their usual family physician and invited to participate actually
agreed to be screened and 14% randomized into the study. The
median ITT follow-up for the primary outcome was 3.0 years (maxi-
mum 6.3 years, total 22 600 person-years). Table 1 shows the base-
line characteristics. A total of 39% of participants were taking
diclofenac, 32% ibuprofen, and 94% had osteoarthritis. The mean age
at entry was 68 years, 59% were female, 15.5% current smokers, 8%
had a history of diabetes, and 44% a history of hypertension. Mean
systolic and diastolic blood pressures were 141 and 78 mmHg,
respectively, and the mean body mass index was 29.7 kg/m2.
In the prescribed celecoxib group, 50.9% withdrew from the
randomized therapy compared with 30.2% not continuing with any
prescribed nsNSAID therapy (P< 0.0001, Figure 1). A total of 6.7%
withdrew informed consent in the celecoxib group compared with
3.9% in the nsNSAID group (P< 0.0001). The reasons recorded for
withdrawal from the drug a participant was initially randomized to
are listed in Table 2.
The mean doses of NSAIDs taken per day in Scotland where full
data were available were 169.8 (SD 80.6) mg for celecoxib, 79.4
(38.3) mg for diclofenac, 675.9 (345.9) mg for ibuprofen, and 581.0
(263.4) mg for naproxen (see Supplementary material online, Table
S7 for these and other NSAIDs).
Amongst patients randomized to celecoxib those who were taking
diclofenac prior to study entry were more likely to withdraw from
celecoxib than patients taking ibuprofen at baseline [HR (95% CI) of
withdrawing from celecoxib by ibuprofen stratum vs. diclofenac stra-
tum¼ 0.84 (0.75, 0.95)].
A total of 278 primary endpoints occurred in 249 (1.12 per 100
patient-years) participants in the ITT analysis, 146 (0.90 per 100-
patient years) of these during the on-treatment period (Table 3 and
Figure 2). In the ITT analysis, 125 participants (1.14 per 100 patient-
years) in the prescribed celecoxib group had a primary outcome
compared with 124 (1.10 per 100 patient-years) in the prescribed
nsNSAID group (HR 1.04; 95% CI, 0.81–1.33; P¼ 0.75). Statistically
significant non-inferiority was demonstrated in the ITT analysis. In the
on-treatment analysis, 65 participants (0.95 per 100 patient-years) in
the celecoxib group had a primary outcome compared with 81 (0.86
per 100 patient-years) in the nsNSAID group (HR 1.12; 95% CI,
0.81–1.55; P¼ 0.50) (see Supplementary material online, Figure S3).
Results for the primary outcome for the initial nsNSAID strata are
shown in Figure 3 and corresponding results for other pre-specified
subgroups in the Supplementary material online, Figure S2. There
were no statistically significant subgroup interactions. Absolute differ-
ences in the rates (celecoxib nsNSAID group) of the primary end-
point were 0.8, 95% CI (0.5, 2.0) events per 1000 patient-years for
Randomized trial of switching from nsNSAIDs to celecoxib 1845
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.. the on-treatment analysis and 0.4, 95% CI (1.1, 1.8) events per
1000 patient-years for the ITT analysis.
Results by arthritis sub-type are given in the Supplementary mate-
rial online, Table S6.
Results for secondary outcomes are reported in Table 3. There
were no statistically significant differences between the randomized
treatment groups for any of the secondary outcomes. Ulcer-related
upper GI complications were uncommon and for the on-treatment
analysis there were only seven patients with events in the prescribed
celecoxib group and five in the prescribed nsNSAID group
(P¼ 0.38), and for the ITT analysis, 10 and 5, respectively (P¼ 0.27).
There were 35 deaths in the celecoxib group and 41 in subjects
prescribed nsNSAIDs in the on-treatment analysis (HR 1.20; 95% CI,
0.76–1.88; P¼ 0.43), and 99 deaths in the celecoxib group compared
with 111 in the nsNSAIDs group by ITT analysis (HR 0.92; 95% CI,
0.70–1.21; P¼ 0.56). There were no statistically significant differences
in cause-specific deaths [CV causes (33.3% celecoxib, 35.3%
nsNSAIDs), neoplasia (39.2% and 29.3%), and non-malignant respira-
tory causes (14.7% vs. 12.9%)] with only two attributed to upper GI
bleeding (both on celecoxib).
Serious and non-serious adverse events are tabulated by the
Medical Dictionary for Regulatory Activities11 system organ class in
the Supplementary material online, Tables S3–S5. There were more
non-serious adverse reactions (ARs) attributed to trial treatment in
the prescribed celecoxib group: 804 (22%) participants with events
vs. 586 (16.1%) in the prescribed nsNSAID group (P< 0.001); how-
ever in an open study, attribution to study drug may be prone to bias.
Overall, more GI ARs were reported on celecoxib than nsNSAIDs
(10.56% vs. 9.12%). There was no statistically significant difference in
serious ARs: 190 (5.2%) participants with events in the celecoxib
group vs. 213 (5.8%) in the nsNSAID group. However, there were
more GI serious ARs on nsNSAIDs than celecoxib (1.81% vs. 1.04%,
P¼ 0.007) with 10 vs. 2 reports of rectal haemorrhage and 13 vs. 3 of
gastritis, respectively. Haematological ARs were reported in more
nsNSAID than celecoxib patients (1.34% vs. 0.66%) largely attribut-
able to more patients with anaemia or iron deficiency anaemia (1.
34% vs. 0.58%). Some (non-serious) ARs appeared to be more
.................................................................................................
Table 1 Characteristics of the patients at baseline
Characteristic Celecoxib nsNSAID
(N 5 3647) (N 5 3650)
Male sex, no. (%) 1527 (41.9) 1432 (39.2)
Current smoker, no. (%) 547 (15.0) 583 (16.0)
Ethnic group (White), no. (%) 3638 (99.8) 3636 (99.6)
Age, years 68.66 6.2 68.26 6.1
Systolic blood pressurea, mmHg 140.56 17.8 140.86 17.9
Diastolic blood pressurea, mmHg 77.66 10.7 77.76 10.7
Heart ratea beats/min 70.86 11.3 70.46 11.1
Body-mass indexb,c 29.66 5.7 29.86 5.6
Waist/Hip ratiod,e 0.916 0.1 0.916 0.1
Histories of, no. (%)
Heart failure (NYHA I/II) 4 (0.1) 10 (0.3)
Diabetes 301 (8.3) 285 (7.8)
High blood pressure 1634 (44.8) 1607 (44.0)
Raised cholesterol 1268 (34.8) 1211 (33.2)
Renal disease 133 (3.6) 125 (3.4)
Peptic ulcer 254 (7.0) 239 (6.5)
Upper GI hospitalization 168 (4.6) 180 (4.9)
Upper GI surgery 88 (2.4) 96 (2.6)
Gout 305 (8.4) 300 (8.2)
Helicobacter pylori eradication 170 (4.7) 154 (4.2)
Asthma 365 (10.0) 362 (9.9)
Chronic obstructive pulmonary disease 158 (4.3) 159 (4.4)
Randomization strataf, no. (%)
Arthritis indication—Osteoarthritis 3421 (93.8) 3422 (93.8)
NSAID strata (Ibuprofen) 1149 (31.5) 1153 (31.6)
NSAID strata (Diclofenac) 1413 (38.7) 1412 (38.7)
Baseline medication, no. (%)
Statins 774 (21.1) 748 (20.5)
Aspirin 421 (11.5) 433 (11.9)
Ulcer healing drug 1401 (38.4) 1357 (37.2)
Total cholesterolg, mg/dL 202.36 42.5 203.46 42.5
HDL cholesterolg, mg/dL 55.66 15.4 55.66 15.4
Triglyceridesh (IQR), mg/dL 143.4
(104.4–204.4)
145.1
(105.3–206.2)
Uric acidi, mg/dL 5.5 6 1.5 5.5 6 1.5
Values are mean 6 SD. There were no statistically significant differences between
the two groups except for age (P¼ 0.006) and sex (P¼ 0.02), with values not
adjusted for multiple testing. Percentages may not total 100 because of rounding.
IQR, denotes interquartile range.
aData on systolic blood pressure, diastolic blood pressure, and heart rate were
not available for one participant in the celecoxib group and three participants in
the nsNSAID group.
bData on body-mass index were not available for two participants in the cele-
coxib group and one participant in the nsNSAID group.
cThe body-mass index is the weight in kilograms divided by the square of the
height in meters.
dData on waist/hip ratio were not available for four participants in the celecoxib
group and one participant in the nsNSAID group.
eThe waist/hip ratio is the waist circumference in centimetres divided by the hip
circumference in centimetres.
fNo P-values were calculated for the arthritis indication or NSAID strata as ran-
domization was stratified according to these factors.
gData on total cholesterol and HDL cholesterol were not available for 386 partic-
ipants in the celecoxib group and 385 participants in the nsNSAID group.
hData on triglycerides were not available for 385 participants in the celecoxib
group and 385 participants in the nsNSAID group.
iData on uric acid were not available for 323 participants in the celecoxib group
and 323 participants in the nsNSAID group.
Figure 1 Withdrawal from randomized treatment group. For the
non-selective non-steroidal anti-inflammatory drugs group this
means complete withdrawal from any non-selective non-steroidal
anti-inflammatory drug. P-values reported are for superiority.
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common on celecoxib than nsNSAIDs such as dermatological, cen-
tral nervous system (CNS), musculoskeletal, and GI.
Discussion
In this study, we collected data to compare the extent to which
switching prescribed nsNSAIDs to prescribed celecoxib affected the
risk of CV, GI, and other adverse outcomes. We found low CV and
upper GI adverse event rates with no statistically significant difference
between prescribed nsNSAIDs and those switched to prescribed cel-
ecoxib for these outcomes or for any other pre-specified secondary
outcome. Only 34% of deaths were CV and only two were due to GI
haemorrhage and there was no evidence of a treatment group differ-
ence in death rates. Results for the primary outcome were consistent
across subgroups. The rates of serious adverse events were similar in
both groups. The pre-specified non-inferiority limit of 1.4 for the HR
for the primary outcome was achieved only using the intention-to
treat-analysis. Despite this, because of the low event rate we were
able to exclude an increased risk of more than two primary out-
comes per 1000 patient-years in on-treatment analysis and 1.8 events
per 1000 patient-years by ITT analysis.
The original power calculation was for 13 682 patients to be fol-
lowed up for 2 years or 27 364 patient-years of exposure to generate
611 primary endpoints with an event rate of about 2% per year.
Figure 2 Primary composite endpoint: (A) on-treatment and (B) intention-to-treat analyses. All-cause mortality: (C) on-treatment and (D) inten-
tion-to-treat analyses. P-values reported are for superiority.
.................................................................................................
Table 2 Recorded reasons for withdrawal from the
specific drug to which the participant was initially
randomized
Parameter Celecoxib nsNSAID
(N5 3647) (N5 3650)
Withdrawal from randomized
medication, no. (%)
1759 (48.2) 1150 (31.5)
Reason for first withdrawal from
randomized medication as noted
at follow-up visits, no. (%)
Adverse event 304 (17.3) 162 (14.1)
Serious adverse event 95 (5.4) 71 (6.2)
Onset of symptoms that limit
tolerability
144 (8.2) 42 (3.7)
Lack of efficacy 409 (23.3) 111 (9.7)
Switch to non-allocated therapy or
discontinuation
242 (13.8) 296 (25.7)
Doctor’s recommendation
(non-AE)
172 (9.8) 218 (19.0)
Protocol violation 7 (0.4) 4 (0.3)
Patient’s request 220 (12.5) 85 (7.4)
Other 166 (9.4) 161 (14.0)
Randomized trial of switching from nsNSAIDs to celecoxib 1847
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.Fewer subjects than expected signed up to take part in the study so
to compensate for this we followed up those randomized for much
longer. In fact, 7297 subjects were followed for an average of 3.2
years giving 23 670 patient-years of exposure (87% of planned). The
adjudicated primary CV event rate was substantially lower than
expected at (observed 0.9% expected> 2%).
Had the study recruited all 13 682 subjects as envisaged, the origi-
nal non-inferiority limit of 1.3 would have required an average of 5
Figure 3 Forest plot for primary endpoint by subgroups of baseline non-steroidal anti-inflammatory drug medication use for the on-treatment and
the intention-to-treat analyses.
.................................................................... ...................................................................
....................................................................................................................................................................................................................
Table 3 Treatment comparisons (celecoxib vs. non-selective non-steroidal anti-inflammatory drugs) for the primary
outcome (and its subcomponents) and all secondary endpoints
On-treatment analysis Intention-to-treat analysis
Celecoxib nsNSAID Celecoxib nsNSAID
Numbers of subjects 3647 3650 3647 3650
Follow-up, years (primary outcome) 6842 9460 10 993 11 318
n (n/100PY) n (n/100PY) HR (95% CI); P n (n/100PY) n (n/100PY) HR (95% CI); P
Primary endpoint 65 (0.95) 81 (0.86) 1.12 (0.81, 1.55); 0.50 125 (1.14) 124 (1.10) 1.04 (0.81, 1.33); 0.75
Hospitalization for non-fatal MI 38 (0.56) 40 (0.42) 1.34 (0.86, 2.09); 0.20 70 (0.63) 56 (0.49) 1.29 (0.91, 1.84); 0.15
Non-fatal stroke 16 (0.23) 25 (0.26) 0.89 (0.47, 1.67); 0.71 31 (0.28) 36 (0.32) 0.89 (0.55, 1.44); 0.63
CV death 15 (0.22) 17 (0.18) 1.22 (0.61, 2.46); 0.57 32 (0.29) 39 (0.34) 0.85 (0.53, 1.35); 0.49
Biomarker positive ACS 0 (0) 1 (0.01) — 0 (0) 1 (0.01) —
Secondary endpoints
(a) Hospitalization or death for upper
GI ulcer complications
7 (0.10) 5 (0.05) 1.96 (0.54, 7.84); 0.38 10 (0.09) 5 (0.04) 2.08 (0.65, 7.74); 0.27
(b) Secondary endpoint (a) or Primary endpoint 72 (1.05) 86 (0.91) 1.16 (0.85, 1.59); 0.34 132 (1.20) 129 (1.14) 1.06 (0.83, 1.35); 0.65
(c) Hospitalization for heart failure 7 (0.10) 10 (0.11) 0.96 (0.31, 2.78); 1.00 11 (0.10) 15 (0.13) 0.76 (0.31, 1.76); 0.61
(d) Secondary endpoint (c) or Primary endpoint 70 (1.02) 86 (0.91) 1.14 (0.83, 1.56); 0.43 130 (1.18) 132 (1.17) 1.02 (0.80, 1.29); 0.90
(e) All-cause mortality 35 (0.51) 41 (0.43) 1.20 (0.76, 1.88); 0.43 99 (0.89) 111 (0.97) 0.92 (0.70, 1.21); 0.56
(f) Hospitalization for new or worsening renal
failure
4 (0.06) 3 (0.03) 1.83 (0.31, 12.49); 0.67 7 (0.06) 8 (0.07) 0.90 (0.28, 2.83); 1.00
1848 T.M. MacDonald et al.
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years follow-up rather than the 2 years envisaged. With 7297 sub-
jects, 611 endpoint would have taken 9.4 years of average follow-up.
The steering committee was of the opinion that abandoning the trial
in the face of these findings would have been nihilistic and unethical
and that adjusting the non-inferiority limit to 1.4 was the more
responsible option.
The low event rates for both CV and GI endpoints are in themselves
of some importance. The trial participants were older subjects with
typical CV risk factors taking chronic NSAID therapy but the low
observed CV event rates make it unlikely that there could be substan-
tial attributable NSAID toxicity either from nsNSAIDs or celecoxib.
Overall withdrawal rates in the trial were relatively high, reflecting
the length of our study but these were actually similar to those seen
at comparable time points in the shorter Celecoxib vs. Omeprazole
and Diclofenac in patients with Osteoarthritis and Rheumatoid
arthritis (CONDOR)12 and Therapeutic Arthritis Research and
Gastrointestinal Event Trial (TARGET) studies.13
We found a higher withdrawal rate from those switched to pre-
scribed celecoxib compared with prescribed nsNSAIDs. It is impor-
tant to note that whilst the trial was open, the steering committee
remained blinded to this differential drop-out rate until after database
lock. The dominant reason recorded for the higher withdrawal in
those allocated to switch to celecoxib was lack of efficacy. We found
that those patients who were prescribed diclofenac prior to random-
ization were more likely to discontinue celecoxib after random-
ization than those prescribed ibuprofen prior to randomization.
Despite studies suggesting that celecoxib is of equivalent effective-
ness as diclofenac14 and that nsNSAIDs for knee arthritis are similarly
effective,15 this study provides some indirect evidence that diclofenac
may be more effective than ibuprofen. A recent network meta-
analysis supports this finding.16 Other reasons for celecoxib discon-
tinuation were poor tolerability and adverse effects suggesting that
celecoxib was not as well tolerated as nsNSAIDs.
Adverse reactions attributed to celecoxib were more common
in some categories, such as dermatological, CNS, musculoskeletal,
and GI. This likely reflects, at least in part, exposure to a new
drug compared with continuing one that subjects had found to
suit them. During the trial there was significant public debate
about COX-2 inhibitor safety which may have dissuaded primary
care physicians from up-titrating celecoxib and influenced overall
withdrawal rates. In addition, EMA warnings about the CV risks of
diclofenac resulted in primary care physicians being unhappy to
continue to prescribe diclofenac,17 resulting in a protocol amend-
ment that allowed patients in the nsNSAID group to switch to
other prescribed nsNSAIDs.
There have been a number of meta-analyses describing the CV
risk related to NSAIDs.3,18 Studies of celecoxib have been observa-
tional or have examined CV toxicity that occurred in randomized
efficacy trials of short duration.19,20 Network meta-analyses have
considered selective COX-2 inhibitors as a group and included trials
with heterogeneous risk groups and included trials of COX-2 agents
with doses much higher than approved for arthritis.3 In contrast, the
biggest observational study of NSAID toxicity found celecoxib to
have one of the lowest CV event rates when used in routine clinical
care.21 In Europe, selective COX-2 inhibitors may only be prescribed
to subjects with no significant CV disease so a study in this low-risk
population with celecoxib as prescribed in normal care was required.
We are confident that the lower than expected CV and GI event
rates in our study are robust. The use of record-linkage to registries
of hospitalizations and deaths maximized event detection and we had
a low threshold for sending events for adjudication.
Falling event rates have been reported for coronary disease across
Europe22 and the USA23 and the low event rates we observed were
similar to those seen in primary prevention studies.24
At baseline, only about 38% of subjects took concurrent ulcer
healing drugs but during the study the UK National Institute for
Health and Care Excellence published two guidelines that advocated
the co-prescription of proton pump inhibitors with chronic NSAID
therapy for osteoarthritis.25,26 This may account for the very low rate
of ulcer-related complications.
A strength of SCOT is that it was a randomized study and had a
number of pragmatic features. Follow-up was primarily by record-
linkage and NSAID therapy was evaluated in a normal primary care
setting. SCOT is thus likely to have good external validity as it reflects
outcomes that occur in usual care. The low CV event rate resulted in
reduced power to establish non-inferiority in the on-treatment analy-
sis than we had anticipated at the design stage, but also supports the
view that any enhancement of CV risk with celecoxib or nsNSAID is
modest. Increasing the size of the trial once the low event rate had
become apparent was not feasible. The differential discontinuation
rate that was not known until investigators were un-blinded further
affected the on-treatment analyses. The reasons for this differential
withdrawal are complex and associated with both patient and pre-
scriber preference, permitted within the ethical constraints of the
study, on a background of adverse publicity about NSAIDs in general
at the time the study was being conducted. We also found lower
rates of NSAID-associated GI complications than previous studies1
possibly reflecting the use of relatively low doses in this setting and
the increasing co-prescription of anti-ulcer drugs. Our results reduce
the rationale for switching patients established on nsNSAIDs to cele-
coxib, particularly in view of the high withdrawal rate of patients
undergoing this strategy.
SCOT studied the clinical use of NSAIDs in standard (or usual)
care in a primary care setting. The results of SCOT are thus exter-
nally valid and highly likely to reflect the real world toxicity and use
of NSAIDs. In order to achieve such externally valid results, SCOT
inevitably had to trade internal validity as might be obtained from a
double-blind study where subjects were given high doses of
NSAIDs. Despite being an open study, the SCOT investigators
were blinded to the results of the study until after database lock.
The fact that there was a differential drop out between celecoxib
and standard NSAIDs is an externally valid finding of this study.
This indicates that subjects were less likely to stay on celecoxib
after the switch. This is important information and whilst it did
result in the non-inferiority margin being non-significant, it did
reflect what is likely to happen in clinical care. The ITT analysis,
which looked at events based only on randomized intention, was
non-inferior. In a pragmatic trial of safety such a result is not unim-
portant. The strategy of switching was non-inferior to staying on
therapy in the trial as a whole. Although the purist might regard a
per-protocol analysis the gold standard for safety, a pragmatic
study does not force a treatment protocol so per-protocol has
less meaning. This is why we called our analysis ‘on-treatment’.
From a philosophical standpoint, an ITT analysis might be argued
Randomized trial of switching from nsNSAIDs to celecoxib 1849
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to be the only sensible analysis for a pragmatic trial so we should
not denigrate the importance of this finding.
We believe that the SCOT study provides important information
on the safety of celecoxib vs. nsNSAIDs in clinical practice in subjects
free from established CV. The low event rates seen in this trial sug-
gest that the attributable risk of nsNSAID or celecoxib therapy is
likely to be acceptably small.
Summary
In individuals with arthritis and without known CV disease, CV event
rates were low and serious ulcer-related complication rates were
very low, and neither outcome differed significantly between
nsNSAIDs and celecoxib. This study could exclude an increase in the
primary CV event rate of more than two events per 1000 patient-
years associated with switching to prescribed celecoxib. However, a
strategy of switching prescribed nsNSAIDs to prescribed celecoxib
in the setting of primary care had no advantage.
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